{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:56:15Z","timestamp":1791482175425,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02399-7","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:30:20Z","timestamp":1791480620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ruzinurad: First Approval"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7191-7391","authenticated-orcid":false,"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"10287","key":"2399_CR1","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, et al. Gout. Lancet. 2021;397(10287):1843\u201355.","journal-title":"Lancet"},{"issue":"6","key":"2399_CR2","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"7","key":"2399_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70375","volume":"28","author":"M Sun","year":"2024","unstructured":"Sun M, Lyu Z, Wang C, et al. 2024 update of Chinese guidelines for diagnosis and treatment of hyperuricemia and gout Part I: recommendations for general patients. Int J Rheum Dis. 2024;28(7):e70375.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2399_CR4","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1038\/s41467-025-60480-3","volume":"16","author":"Y Suo","year":"2025","unstructured":"Suo Y, Fedor JG, Zhang H, et al. Molecular basis of the urate transporter URAT1 inhibition by gout drugs. Nat Commun. 2025;16(1):5178.","journal-title":"Nat Commun"},{"key":"2399_CR5","unstructured":"Jiangsu Hengrui Pharmaceuticals Co. Ruzinurad sodium tablets (\u745e\u9e23\u00ae): Chinese prescribing information [Chinese]. 2026. https:\/\/www.hnysfww.com\/data\/m_c\/1780514200341079118.pdf. Accessed 23 Aug 2026."},{"key":"2399_CR6","unstructured":"National Medical Products Administration. \u56fd\u5bb6\u836f\u76d1\u5c40\u6279\u51c6\u9c81\u5179\u8bfa\u96f7\u94a0\u7247\u4e0a\u5e02 [The National Medical Products Administration has approved the marketing of ruzinurad sodium tablets] [Chinese]. 28 May 2026. https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20260528144524113.html."},{"key":"2399_CR7","unstructured":"Jiangsu Hengrui Pharmaceuticals Co. Overseas regulatory announcement [media release]. 28 May 2026. https:\/\/www1.hkexnews.hk\/listedco\/listconews\/sehk\/2026\/0528\/2026052802151.pdf."},{"key":"2399_CR8","unstructured":"Jiangsu Hengrui Pharmaceuticals Co. Data on file. 2026"},{"issue":"2","key":"2399_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jcph.2159","volume":"63","author":"C Wang","year":"2023","unstructured":"Wang C, Yu Q, Jiang X, et al. A drug\u2013drug interaction study of a novel selective urate reabsorption inhibitor, SHR4640, and xanthine oxidase inhibitor, febuxostat, in patients with primary hyperuricemia. J Clin Pharmacol. 2023;63(2):1\u201311.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2399_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1124\/dmd.121.000581","volume":"50","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Zhang H, Liu M, et al. Pharmacokinetics, mass balance, and metabolism of the novel urate transporter 1 inhibitor [14C]HR011303 in humans: metabolism is mediated predominantly by UDP-glucuronosyltransferase. Drug Metab Dispos. 2022;50(6):798\u2013808.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2399_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/cpdd.1191","volume":"12","author":"B Liang","year":"2023","unstructured":"Liang B, Wang J, Bai N, et al. Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of SHR4640, a selective urate transporter 1 inhibitor, in healthy Chinese male volunteers. Clin Pharmacol Drug Dev. 2023;12(4):392\u20136.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"2399_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17425255.2024.2428367","volume":"21","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Hu X, Pei Z, et al. Evaluating the drug-drug interactions of SHR4640 on repaglinide and midazolam in healthy subjects. Expert Opin Drug Metab Toxicol. 2025;21(2):217\u201324.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 1","key":"2399_CR13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ard.2025.05.304","volume":"84","author":"H Ding","year":"2025","unstructured":"Ding H, Bao C, Hu J, et al. Ruzinurad for hyperuricemia associated with primary gout: a multicenter, randomized, double-blind, active-controlled, phase 3 study [abstract no. OP0302]. Ann Rheum Dis. 2025;84(Suppl 1):240\u20131.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2399_CR14","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1093\/rheumatology\/keab198","volume":"60","author":"Y Lin","year":"2021","unstructured":"Lin Y, Chen X, Ding H, et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford). 2021;60(11):5089\u201397.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"2399_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2024-eular.4573","volume":"83","author":"C Bao","year":"2024","unstructured":"Bao C, Ding H, Dai Q, et al. A 12-week, multicenter, randomized, double-blind, placebo-controlled, phase 2 study of ruzinurad (SHR4640) in combination with febuxostat for primary gout and hyperuricemia with an inadequate response to febuxostat alone [abstract no. OP0129]. Ann Rheum Dis. 2024;83(Suppl 1):86\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2399_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X211067304","volume":"14","author":"H Tang","year":"2022","unstructured":"Tang H, Cui B, Chen Y, et al. Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study. Ther Adv Musculoskelet Dis. 2022;14:1\u201310.","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02399-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02399-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02399-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:30:21Z","timestamp":1791480621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02399-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":16,"alternative-id":["2399"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02399-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"24 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}